Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.

Area of Science:

• Oncology
• Preventive Medicine
• Pharmacology

Background:

• Breast cancer is a leading cause of cancer death in US women, with an estimated 1 in 8 developing the disease.
• African American women face a disproportionately higher mortality rate from breast cancer.
• Risk assessment and medication use are key strategies for primary breast cancer prevention.

Purpose of the Study:

• To update the 2013 US Preventive Services Task Force (USPSTF) recommendation on medications for primary breast cancer risk reduction.
• Evaluate the accuracy of risk assessment tools and the efficacy/safety of risk-reducing medications.

Main Methods:

• Systematic review of evidence including randomized trials, observational studies, and diagnostic accuracy studies.
• Focused on women without a current or previous diagnosis of breast cancer or ductal carcinoma in situ.
• Assessed risk stratification models, medication effectiveness, adverse effects, and subgroup variations.

Main Results:

• Risk assessment tools modestly predict population-level breast cancer incidence but have limited individual predictive accuracy.
• Risk-reducing medications (tamoxifen, raloxifene, aromatase inhibitors) offer moderate benefits for invasive, estrogen receptor-positive breast cancer in high-risk postmenopausal women.
• Benefits are small in women not at increased risk; medications carry small to moderate harms.

Conclusions:

• Clinicians should offer risk-reducing medications to women at increased breast cancer risk with low risk of adverse effects (USPSTF B recommendation).
• Routine use of these medications is not recommended for women not at increased risk (USPSTF D recommendation).
• Recommendations apply to asymptomatic women aged 35+ with specific benign breast conditions, excluding those with current/prior breast cancer diagnoses.